Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Stock Slides 8.3 Percent on Revenue Investigation, Delayed Q3 Earnings

NEW YORK, Nov. 7 (GenomeWeb News) - Shares in Ciphergen Biosystems were down 8.3 percent, or $.16, at $1.77 in mid-afternoon trading after the company said an audit committee has begun investigating $500,000 in sales recorded in the second quarter.

 

As GenomeWeb News reported earlier today, the company will delay releasing its financial results for the third quarter while the investigation is pending.

 

Ciphergen is expected to file a late notice with the Securities and Exchange Commission for its quarterly report.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.